Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease

Experimental Neurology

Volumn 165, Issue 1, 2000, Pages 136-142

  Nash, J E ^a   Fox, S H ^a   Henry, B ^a   Hill, M P ^b   Peggs, D ^a   McGuire, S ^b   Maneuf, Y ^a   Hille, C ^a   Brotchie, J M ^a   Crossman, A R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Williams House   (United Kingdom)

Author keywords

Dyskinesia; NR2B selective NMDA receptor antagonists; Parkinson's disease; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; IFENPRODIL; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL MODEL; ARTICLE; BODY POSTURE; BRADYKINESIA; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFECT; DYSKINESIA; MOTOR ACTIVITY; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033834442     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7444     Document Type: Article

References (62)

1. 3H]MK-801 binding to N-methyl-D-aspartate receptors solubilised from rat brain: Effect of glycine site ligands, polyamines, ifenprodil and desipramine
2. The MPTP model: Versatile contributions to the treatment of idiopathic Parkinson's disease
3. Chemical signalling in the globus pallidus in parkinsonian
4. Novel approaches to the symptomatic treatment of parkinsonian syndromes: Alternatives and adjuncts to dopamine replacement
5. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease
6. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease
7. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice
8. Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice
9. Interfering with glutamatergic transmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems
10. The non-competetive NMDA antagonists MK-801 and PCP, as well as the competetive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice
11. Parkinson's disease treated with a suspected dopamine receptor agonist
12. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey
13. Neural mechanisms in disorders of movement
14. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A
15. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations
16. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease
17. Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease
18. Adenosine A(2a) antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
19. Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (+)-HA-966 in an experimental model of Parkinson's disease
20. N-methyl-D-aspartate antagonists stimulate locomotor activity in monoamine-depleted rats: Implications for the therapy of Parkinson's disease
21. Toward an understanding of the role of glutamate in experimental parkinsonism: Agonist-sensitive sites in the basal ganglia
22. New medical and surgical treatments for Parkinson's disease
23. Mutational analysis of the glycine-binding site of the NMDA receptor: Structural similarity with bacterial amino acid-binding proteins
24. Molecular diversity of the NMDA receptor channel
25. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
26. MPTP-induced parkinsonism in human and non-human primates - Clinical and experimental aspects
27. 1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra
28. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Implications for treatment and the pathogenesis of Parkinson's disease
29. MPTP: Insights into the etiology of Parkinson's disease
30. The etiology of Parkinson's disease with emphasis on the MPTP story
31. The NMDA2B antagonist Ro 25-6981 is an anti-parkinsonian agent
32. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus
33. Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: Implications for the treatment of Parkinson's disease
34. Tyrosine phosphorylation of NMDA receptors in rat striatum: Effects of 6-OHDA Lesions
35. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism
36. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: Relative contribution of the striatopallidal and striatonigral pathways are suggested by 2-deoxyglucose uptake
37. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3-6-tetrahydropyridine
38. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset
39. Influence of age on N-methyl D-asparate antagonist binding sites in the rat brain studies by in vitro autoradiography
40. Heteromeric NMDA receptor: Molecular and functional distinction of subtypes
41. NMDA receptor subtype selectivity: Eliprodil, polyamine spider toxins, dextromexthorphan and desipramine selectivity block NMDA evoked acetylcholine but not spermidine release
42. Anti-parkinsonian effect of NR2B-selective NMDA antagonists in animal models of Parkinson's disease: A striatal mechanism of action?
43. A novel treatment for Parkinson's disease based upon blockade of NR2B-containing NMDA receptors
44. Do the Anti-Parkinsonian Agents Adenosine A(2a) Antagonists and NR2B-Selective NMDA Antagonists Share a Common Mechanism of Action?
45. Anti-parkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat
46. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intracerebral microinjection studies in the 6-OHDA-lesioned rat
47. 3H]spermidine from rat striatal slices in vitro
48. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: Effect of dopaminergic denervation and L-DOPA administration
49. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal nmda receptor subunits
50. γ-Aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle
51. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)
52. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-DOPA in the MPTP-treated marmoset
53. Young onset Parkinson's disease
54. 3H]flunitrazepam autoradiography
55. Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: An intracerebral microdialysis study of γ-aminobutyric acid in the lateral segment of the globus pallidus
56. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: A target for neuroprotection
57. Organisation of N-methyl-D-asparatate glutamate receptor gene expression in the basal ganglia of the rat
58. Identification of a long variant of mRNA encoding the NR3 subunit of the NMDA receptor: Its regional distribution and developmental expression in the rat brain
59. MPTP-induced parkinsonism as a model for Parkinson's disease
60. Elevated NMDA receptors in parkinsonian striatum
61. Ifenprodil discriminates subtype of the N-methyl-D-aspartate receptors: Selectivity and mechanisms at recombinant heteromeric receptors
62. The competitive NMDA antagonists CGP 40.116 enhances L-DOPA response in MPTP-treated marmosets